A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors

被引:194
作者
Candelaria, M.
Gallardo-Rincon, D.
Arce, C.
Cetina, L.
Aguilar-Ponce, J. L.
Arrieta, O.
Gonzalez-Fierro, A.
Chavez-Blanco, A.
de la Cruz-Hernandez, E.
Camargo, M. F.
Trejo-Becerril, C.
Perez-Cardenas, E.
Perez-Plasencia, C.
Taja-Chayeb, L.
Wegman-Ostrosky, T.
Revilla-Vazquez, A.
Duenas-Gonzalez, A.
机构
[1] Univ Nacl Autonoma Mexico, Direct Invest, Inst Nacl Cancerol, Inst Invest Biomed,Unidad Invest Biomed Canc, Mexico City 14080, DF, Mexico
[2] Inst Nacl Cancerol, Div Invest Clin, Mexico City, DF, Mexico
[3] Inst Nacl Cancerol, Div Med, Mexico City, DF, Mexico
关键词
epigenetic therapy; hydralazine; magnesium valproate; phase II; refractory; solid tumors;
D O I
10.1093/annonc/mdm204
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Epigenetic aberrations lead to chemotherapy resistance; hence, their reversal by inhibitors of DNA methylation and histone deacetylases may overcome it. Patients and methods: Phase 11, single-arm study of hydralazine and magnesium valproate added to the same schedule of chemotherapy on which patients were progressing. Schedules comprised cisplatin, carboplatin, paclitaxel, vinorelbine, gemcitabine, pemetrexed, topotecan, doxorubicin, cyclophosphamide, and anastrozole. Patients received hydralazine at 182 mg for rapid, or 83 mg for slow, acetylators, and magnesium valproate at 40 mg/kg, beginning a week before chemotherapy. Response, toxicity, DNA methylation, histone deacetylase activity, plasma valproic acid, and hydralazine levels were evaluated. Results: Seventeen patients were evaluable for toxicity and 15 for response. Primary sites included cervix (3), breast (3), lung (1), testis (1), and ovarian (7) carcinomas. A clinical benefit was observed in 12 (80%) patients: four PR, and eight SD. The most significant toxicity was hematologic. Reduction in global DNA methylation, histone deacetylase activity, and promoter demethylation were observed. Conclusions: The clinical benefit noted with the epigenetic agents hydralazine and valproate in this selected patient population progressing to chemotherapy' and re-challenged with the same chemotherapy schedule after initiating hydralazine and valproate' lends support to the epigenetic-driven tumor-cell chemoresistance hypothesis (ClinicalTrials.gov Identifier: NCT00404508).
引用
收藏
页码:1529 / 1538
页数:10
相关论文
共 42 条
[1]   Hematologic toxicity of sodium valproate [J].
Acharya, S ;
Bussel, JB .
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2000, 22 (01) :62-65
[2]   Computational studies of 1-hydrazinophthalazine (hydralazine) as an antineoplasic agent.: Docking studies on methyltransferase [J].
Angeles, E ;
Vázquez-Valadéz, VH ;
Vázquez-Valadéz, O ;
Velázquez-Sánchez, AM ;
Ramírez, A ;
Martínez, L ;
Díaz-Barriga, S ;
Romero-Rojas, A ;
Cabrera, G ;
López-Castañares, R ;
Dueñas-González, A .
LETTERS IN DRUG DESIGN & DISCOVERY, 2005, 2 (04) :282-286
[3]   Hydralazine target:: From blood vessels to the epigenome [J].
Arce, C ;
Segura-Pacheco, B ;
Perez-Cardenas, E ;
Taja-Chayeb, L ;
Candelaria, M ;
Dueñas-Gonzalez, A .
JOURNAL OF TRANSLATIONAL MEDICINE, 2006, 4 (1)
[4]   A Proof-Of-Principle Study of Epigenetic Therapy Added to Neoadjuvant Doxorubicin Cyclophosphamide for Locally Advanced Breast Cancer [J].
Arce, Claudia ;
Perez-Plasencia, Carlos ;
Gonzalez-Fierro, Aurora ;
de la Cruz-Hernandez, Erick ;
Revilla-Vazquez, Alma ;
Chavez-Blanco, Alma ;
Trejo-Becerril, Catalina ;
Perez-Cardenas, Enrique ;
Taja-Chayeb, Lucia ;
Bargallo, Enrique ;
Villarreal, Patricia ;
Ramirez, Teresa ;
Vela, Teresa ;
Candelaria, Myrna ;
Camargo, Maria F. ;
Robles, Elizabeth ;
Duenas-Gonzalez, Alfonso .
PLOS ONE, 2006, 1 (01)
[5]   Altered expression of topoisomerase IIα contributes to cross-resistant to etoposide K562/MX2 cell line by aberrant methylation [J].
Asano, T ;
Nakamura, K ;
Fujii, H ;
Horichi, N ;
Ohmori, T ;
Hasegawa, K ;
Isoe, T ;
Adachi, M ;
Otake, N ;
Fukunaga, Y .
BRITISH JOURNAL OF CANCER, 2005, 92 (08) :1486-1492
[6]   Nitroso-urea-cisplatin-based chemotherapy associated with valproate: Increase of haematologic toxicity [J].
Bourg, V ;
Lebrun, C ;
Chichmanian, RM ;
Thomas, P ;
Frenay, M .
ANNALS OF ONCOLOGY, 2001, 12 (02) :217-219
[7]   Cytostatic drug treatment causes seeding of gene promoter methylation [J].
Bredberg, Anders ;
Bodmer, Walter .
EUROPEAN JOURNAL OF CANCER, 2007, 43 (05) :947-954
[8]  
Buermeyer AB, 1999, CANCER RES, V59, P538
[9]   Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia [J].
Bug, G ;
Ritter, M ;
Wassmann, B ;
Schoch, C ;
Heinzel, T ;
Schwarz, K ;
Romanski, A ;
Kramer, OH ;
Kampfmann, M ;
Hoelzer, D ;
Neubauer, A ;
Ruthardt, M ;
Ottmann, OG .
CANCER, 2005, 104 (12) :2717-2725
[10]   Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer [J].
Cameron, EE ;
Bachman, KE ;
Myöhänen, S ;
Herman, JG ;
Baylin, SB .
NATURE GENETICS, 1999, 21 (01) :103-107